UBS’s Acceleron Pharma XLRN Stock Holding History

UBS’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,713	Closed	-$58K	–	10915
2014 Q2	$58K	Buy	+1,713	New	+$57.3K	﹤0.01%	6678

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS's XLRN Position: Q3 2014 in Review

UBS sold out of Acceleron Pharma (XLRN) in Q3 2014, closing a stake of 1,713 shares — an estimated $58K sold.

UBS first reported a position in XLRN in Q2 2014 and held it in 1 quarter. The position peaked at $58K in Q2 2014. 84 funds tracked by Wall St. Rank hold XLRN as of Q3 2014.

UBS reported no remaining Acceleron Pharma position as of Q3 2014 after selling out during the quarter.
UBS sold 1,713 Acceleron Pharma shares in Q3 2014, an estimated $58K.
UBS first reported a position in Acceleron Pharma in Q2 2014 and held it in 1 quarter.
UBS's Acceleron Pharma position peaked at $58K in Q2 2014.
84 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.